Рівень маркерів системного запалення і клінічний перебіг стабільної ішемічної хвороби серця в пацієнтів зі стенозувальним атеросклерозом коронарних артерій та без нього

В.Й. Целуйко, Т.В. Пильова

Література  

1. AlBadri A., Lai K., Wei J. et al. Inflammatory biomarkers as predictors of heart failure in womenwithout obstructive coronary artery disease: A report from the NHLBI-sponsored Women’s Ischemia SyndromeEvaluation (WISE) // PLoSONE.– 2017.– Vol. 12 (5).– P. e0177684. doi: 10.1371/journal. pone.01776845.
2. Al-Khatib S.M., Stevenson W.G., Ackerman M.J. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society // Circulation.– 2018.– Vol. 138 (13).– P. e272–e391. doi: 10.1161/CIR.0000000000000549.
3. AlMahameed S.T., Ziv O. Ventricular Arrhythmias // Med. Clin. North Am.– 2019.– Vol. 103 (5).– P. 881–895. doi: 10.1016/j.mcna.2019.05.008.
4. Austen W.G., Edwards J.E., Frye R.L. et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association // Circulation.– 1975.– Vol. 51.– P. 5–40.
5. Brainin P, Frestad D, Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: a systematic review and meta-analysis // Int. J. Cardiol.– 2018.– Vol. 254.
6. Daniels L.B. Pretenders and contenders: inflammation, c-reactive protein, and interleukin-6 // J. Am. Heart Assoc.– 2017.– Vol. 6 (10).– P. e007490.
7. Gager G.M., Biesinger B., Hofer F. et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome // Vascul. Pharmacol.– 2020.– Vol. 135.– P. 106806.
8. Held C., White H.D., Stewart R.A.H. et al. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial // J. Am. Heart Assoc.– 2017.– Vol. 6 (10).– P. e005077.
9. Kaptoge S., Seshasai S.R., Gao P. et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis // Eur. Heart J.– 2014.– Vol. 35 (9).– P. 578–589.
10. Kunadian V., Chieffo A., Camici P.G. et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group // Eur. Heart J.– 2020.– Vol. 41, Issue 37.– P. 3504–3520. doi: 10.1093/eurheartj/ehaa503.
11. Levey A.S., Lesley A. et al. A New Equation to Estimate Glomerular Filtration Rate // Ann. Intern. Med.– 2009.– Vol. 150 (9).– P. 604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
12. Ma J., Chen X. Anti-inflammatory therapy for coronary atherosclerotic heart disease: unanswered questions behind existing successes // Front Cardiovasc. Med.– 2021.– Vol. 7.– P. 631398.
13. Niccoli G., Scalone G., Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: mechanisms and management // J. Am. Heart Assoc.– 2012.– Vol. 1 (3).– P. e001388. doi: 10.1161/JAHA.112.001388.
14. Pai J.K., Pischon T., Ma J. et al. Inflammatory markers and the risk of coronary heart disease in men and women // New Engl. J. Med.– 2004.– Vol. 351 (25).– P. 2599–2610. doi: 10.1056/NEJMoa040967.
15. Pargaonkar V.S., Kobayashi Y., Kimura T. et al. Accuracy of non-invasive stress testing in women and men with angina in the absence of obstructive coronary artery disease // Int. J. Cardiol.– 2019.– Vol. 282.– P. 7–15.
16. Ridker P.M., Libby P., MacFadyen J.G. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) // Eur. Heart J.– 2018.– Vol. 39 (38).– P. 3499–3507.
17. Ridker P.M., MacFadyen J.G., Glynn R.J. et al. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial // Eur. Heart J.– 2020.– Vol. 41 (31).– P. 2952–2961.
18. Taqueti V.R., Hachamovitch R., Murthy V.L. et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization // Circulation.– 2015.– Vol. 131.– P. 19–27.
19. Thygesen K., Alpert J.S., Jaffe A.S. et al. ESC Scientific Document Group; Fourth universal definition of myocardial infarction Fourth Universal Definition of Myocardial Infarction // J. Am. Coll. Cardiol.– 2018.– Vol. 72 (18).– P. 2231–2264. doi: 10.1016/j.jacc.2018.08.1038.
20. Tong D.C., Whitbourn R., MacIsaac A. et al. High-sensitivity C-reactive protein is a predictor of coronary microvascular dysfunction in patients with ischemic heart disease // Front. Cardiovasc. Med.– 2018.– Vol. 4.– P. 81.